Eton Pharmaceuticals Inc logo

Eton Pharmaceuticals Inc(ETON)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
2-STAR RATING
Consider higher Upturn Star rating
BUY for 6 days
PROFIT SINCE LAST BUY
-9.37% ▼
LAST CLOSE
$61.99
11/18/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for ETON

11/18/2026: ETON (2-star) has a low Upturn Star Rating. Not recommended to BUY.

Eton Pharmaceuticals is a commercial-stage specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases. The company's core strengths include a consistent track record of sequential quarterly revenue growth, high gross margins, and successful product rollouts like ALKINDI SPRINKLE and Increlex. Its primary investment story centers on expanding rare disease franchises and executing high-value product acquisitions. However, key risks involve product revenue concentration, execution challenges in scaling new launches, and potential regulatory or reimbursement hurdles. The stock suits growth-oriented investors willing to accept small-cap volatility while monitoring ongoing product adoption metrics and pipeline catalysts.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitEton delivers rapid year-over-year revenue expansion driven by rare disease product rollouts and strategic acquisitions.
Momentum investorStrong fit while signal remains positiveThe stock frequently attracts momentum interest following sequential revenue beats and new product launch catalysts.
Value investorMixed fitWhile trading at profitable multiples relative to sales, valuation reflects high growth expectations typical of emerging biopharma.
Dividend investorWeak fitThe company retains all earnings to fund commercial expansion and does not pay dividends.
Low-risk investorWeak fitSmall-cap pharmaceutical equities carry inherent execution, regulatory, and market volatility risks.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighSmall-cap pharmaceutical stocks experience sharp price swings based on quarterly sales reports and clinical updates.
Valuation riskMedium / highExpectations for continued hyper-growth leave little room for operational missteps or missed commercial targets.
Competition risk (specialty pharma and generic substitution)MediumEton must protect its niche product lines from alternate treatments and potential generic market entrants.
Business qualityMedium / highThe company features high gross margins and a disciplined asset-acquisition model, though commercial scale is still developing.
Dividend incomeLow / noneNo dividend is distributed, making the stock unsuitable for income-focused strategies.
Execution riskMedium / highSuccessful performance relies heavily on the effective commercial scaling of newly acquired products and pipeline approvals.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.84B USD
Price to earnings Ratio 41.33
1Y Target Price 80.75
Price to earnings Ratio 41.33
1Y Target Price 80.75
Volume (30-day avg) 561.8K shares
Beta 0.83
52 Weeks Range 14.27 - 70.64
Updated Date 11/18/2026
52 Weeks Range 14.27 - 70.64
Updated Date 11/18/2026
Dividends yield (FY) -
Basic EPS (TTM) 1.54

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.0%
Active BUY / eligible
67 / 108
30-Day BUY Count Change
+22
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Drug Manufacturers - Specialty & Generic

BUY participation
91.7%
Active BUY / eligible
11 / 12
30-Day BUY Count Change
+6

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit 505.98%
Avg. Invested days 47
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 5.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/18/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
ETON receives a 3-star rating, supported by solid company fundamentals, and solid analyst coverage. The rating is constrained by soft unit economics.

Company Fundamentals

★★★★★
ETON has solid overall fundamentals (4 stars), with moderate financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, solid cash generation (FCF margin 12.7%) and strong revenue growth (+104.9%) are partially offset by negative earnings growth (-20.4%), weak profitability (net margin -5.8%), modest insider ownership of 4.85%.

Financial Health Rating

★★★★★
ETON's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 24.0%). Profitability is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is ETON's strongest growth driver at +980.7% FY2025 versus FY2024 (strong, 5 stars). By comparison, revenue growth (+104.9%, strong) is also strong, while earnings growth (-20.4%, negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 77.9% and approximately 79.1% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 4.85% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

Opaleye Management Inc 9.92%
Nantahala Capital Management, LLC 8.16%
EcoR1 Capital, LLC 7.53%
BlackRock Inc 6.58%
Vanguard Capital Management, LLC 3.39%

Unit Economics (Per $1K Revenue)

★★★★★
ETON generates approximately $535 of gross profit, $1 of operating income, and $127 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Moderate margins explain the 2-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -0.94% (Tax Credit)

Quantitative Style Profile

★★★★★
ETON has a high-quality, liquid profile. Soft valuation is the primary drawback.

Style Classification

Quality Focused

Quality TiltSmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Product Sales & RoyaltiesCommercial sales of proprietary rare disease medications including ALKINDI SPRINKLE, Increlex, Carglumic Acid, and Galzin.This is the primary engine of Eton's business, generating the vast majority of its recurring revenues.
Licensing & PartneringUpfront payments, development milestones, and commercial royalties from out-licensed pharmaceutical assets.Provides supplementary non-core income that can fluctuate period by period.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2026-11-05
When After Market
Estimate 0.34
Actual 1.06

Profitability

Profit Margin 35.35%
Operating Margin (TTM) 31.3%

Management Effectiveness

Return on Assets (TTM) 21.08%
Return on Equity (TTM) 90.62%

Valuation

Trailing PE 41.33
Forward PE 20.75
Enterprise Value 1.81B
Price to Sales(TTM) 13.01
Enterprise Value 1.81B
Price to Sales(TTM) 13.01
Enterprise Value to Revenue 12.84
Enterprise Value to EBITDA 39.66
Shares Outstanding 28.84M
Shares Floating 22.82M
Shares Outstanding 28.84M
Shares Floating 22.82M
Percent Insiders 4.85
Percent Institutions 77.88

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.